EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Sex-Specific Mediation of Pre-Quit Smoking Reduction: Secondary Analysis of a Randomized Controlled Trial Extending Varenicline Preloading

Samantha Johnstone iD, Robert K Cooper iD, Jennifer M Wray, Sarah Tonkin iD, Kyler S Knapp, Craig R Colder, Eugene Maguin, Martin C Mahoney, Stephen T Tiffany, Thomas H Brandon, Rebecca L Ashare iD, Larry W Hawk iD

Nicotine and Tobacco Research · 2025

DOI: 10.1093/ntr/ntaf100 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Nicotine and Tobacco Research, 2025. Verfasst von Samantha Johnstone und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychology, University at Buffalo, Buffalo, NY, USA. Hauptthemen laut MEDLINE: Smoking, Smoking Cessation, Smoking Cessation Agents, Smoking Reduction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, NCATS/NIH, University of Buffalo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Relative to other pharmacotherapies for smoking cessation, varenicline has significantly greater efficacy in females; however, sex-specific mechanisms have not yet been investigated. We conducted a secondary analysis of ecological momentary assessment data to assess whether reductions in craving, negative affect, and smoking satisfaction/reward/aversion mediate effects of varenicline on next-day smoking to a greater degree in females (n = 179) relative to males (n = 141). Aims and Methods Data were from a 3-week medication manipulation period during the pre-quit phase of a double-blind randomized placebo-controlled trial investigating extended preloading (4 weeks) versus standard preloading of varenicline (1 week, preceded by 3 weeks of placebo, NCT03262662). Time-invariant multi-level moderated mediation models and time-varying mediation models were utilized.

Results

A significant time-varying indirect effect through craving that increased in magnitude over the pre-quit period was identified only in females. Exploratory analysis found that decreases in psychological reward and smoking satisfaction mediated the relationship between varenicline and reductions in craving only in females. Time-invariant multi-level models did not evidence a significant indirect effect through candidate mediators in males or females; the index of moderated mediation was not significant in any of the models.

Conclusions

Our findings suggest that the efficacy of varenicline on reductions in pre-quit smoking in females operates through reductions in craving. Furthermore, reductions in craving may be due to decreases in positive subjective experiences of smoking. Augmenting craving coping strategies as well as reducing smoking reward and satisfaction may be a beneficial approach in females.

Implications

This is the first study to investigate sex-specific mediation of varenicline on reductions in pre-quit smoking. Further investigation into varenicline-induced changes in smoking reinforcement and craving is warranted, particularly in females. For example, experimentally manipulating these mediators may inform them as mechanisms for smoking reduction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SmokingSmoking CessationSmoking Cessation AgentsSmoking ReductionVareniclineAdultFemaleHumansMaleMiddle AgedCravingDouble-Blind MethodEcological Momentary AssessmentSex Factors

Substanzen

Smoking Cessation AgentsVarenicline

Autor:innen und Institutionen

  • Department of Psychology, University at Buffalo, Buffalo, NY, USA.
  • Mental Health Service 116, Ralph H Johnson Veteran's Affairs Healthcare System, Charleston, SC, USA.
  • Health Promotion Research Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • School of Social Work, University at Buffalo, Buffalo, NY, USA.
  • Departments of Internal Medicine and Health Behavior, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Department of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA.

ORCID-Profile: Samantha Johnstone, Robert K Cooper, Sarah Tonkin, Rebecca L Ashare, Larry W Hawk

Förderung

  • NCATS NIH HHS
  • NCATS/NIH
  • University of Buffalo
  • University of Rochester

Zitieren

APA

Johnstone, S., Cooper, R. K., Wray, J. M., Tonkin, S., Knapp, K. S., Colder, C. R., Maguin, E., Mahoney, M. C., Tiffany, S. T., Brandon, T. H., Ashare, R. L., & Hawk, L. W. (2025). Sex-Specific Mediation of Pre-Quit Smoking Reduction: Secondary Analysis of a Randomized Controlled Trial Extending Varenicline Preloading. Nicotine and Tobacco Research. https://doi.org/10.1093/ntr/ntaf100

Vancouver

Johnstone S, Cooper RK, Wray JM, Tonkin S, Knapp KS, Colder CR, et al. Sex-Specific Mediation of Pre-Quit Smoking Reduction: Secondary Analysis of a Randomized Controlled Trial Extending Varenicline Preloading. Nicotine and Tobacco Research. 2025. doi:10.1093/ntr/ntaf100

BibTeX
@article{Johnstone2025,
  author = {Johnstone, Samantha and Cooper, Robert K and Wray, Jennifer M and Tonkin, Sarah and Knapp, Kyler S and Colder, Craig R and Maguin, Eugene and Mahoney, Martin C and Tiffany, Stephen T and Brandon, Thomas H and Ashare, Rebecca L and Hawk, Larry W},
  title = {Sex-Specific Mediation of Pre-Quit Smoking Reduction: Secondary Analysis of a Randomized Controlled Trial Extending Varenicline Preloading},
  journal = {Nicotine and Tobacco Research},
  year = {2025},
  doi = {10.1093/ntr/ntaf100}
}
Kostenlos starten →